Lupin Gears For Europe Specialty Push With Orphan NaMuscla
Executive Summary
Lupin’s rare disease drug, NaMuscla, has been recommended for marketing authorization in Europe – a key milestone for the firm as it shapes its play in the specialty segment. The company may consider taking NaMuscla to other markets such as Japan as well and also add assets to its neuroscience portfolio.